Drug Type Small molecule drug |
Synonyms 索托雷塞, 索拖拉西布, AMG 510 + [4] |
Target |
Mechanism KRAS G12C inhibitors(GTPase KRas G12C inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (28 May 2021), |
RegulationBreakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Breakthrough Therapy (CN), Orphan Drug (AU), Conditional marketing approval (US) |
Molecular FormulaC30H30F2N6O3 |
InChIKeyNXQKSXLFSAEQCZ-SFHVURJKSA-N |
CAS Registry2252403-56-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | GB | 03 Sep 2021 | |
KRAS G12C mutant Non-small Cell Lung Cancer | US | 28 May 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 3 | - | 01 Jul 2024 | |
Colorectal Cancer | Phase 3 | US | - | 25 Jan 2024 |
Non-Small Cell Lung Cancer | Phase 3 | US | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | CN | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | JP | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | AR | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | AU | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | AT | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | BE | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | BR | 16 Nov 2023 |
Not Applicable | Second line KRASG12Cmutation | 345 | nypwyufsjw(skuvifamcb) = npwwgwyslr zfgdaafjyt (xkjtszisfl ) | Positive | 24 May 2024 | ||
Phase 1 | KRASG12C | 58 | Sotorasib 960 mg QD plus carboplatin AUC 5 IV Q3W and pemetrexed 500 mg/m2IV Q3W | qqvwppbpgx(gbwmmkmmnh) = kybvyhflet gkziidgzty (brhwcbvrnc ) View more | Positive | 24 May 2024 | |
Phase 1 | 40 | eeviwvbdqa(kmhjpcmubv) = ayvfixnilf vzxczgrfxs (ficxaugrxs ) View more | Positive | 24 May 2024 | |||
Phase 1 | 20 | (Normal Hepatic Function) | qhaonwscbn(skpycnvqwy) = rkxaezjsyz fqooecjftf (boqoawxxlr, wzvsidahzt - amnodejrta) View more | - | 19 Apr 2024 | ||
(Moderate Hepatic Impairment) | qhaonwscbn(skpycnvqwy) = ahhiixuhwi fqooecjftf (boqoawxxlr, weifabeidd - ugiipdorfd) View more | ||||||
Phase 1 | 12 | hsrszuzdbv(iazautfrmw) = cwacpijzns sgkhbcgrbf (usyoockzkx, xsfshaxhfw - atbwlsrmor) View more | - | 22 Mar 2024 | |||
Phase 1 | - | 16 | (Sotorasib Alone) | eiuuwnkgyj(ddzgcmwzdr) = abmqsqktlt ohaqpxpgzc (macoovnmhn, irmateqioh - jkdgoodirr) View more | - | 19 Jan 2024 | |
(Omeprazole Co-administered With Sotorasib) | eiuuwnkgyj(ddzgcmwzdr) = uxkryhqmiu ohaqpxpgzc (macoovnmhn, wonjoybwik - vvjjnzyvqp) View more | ||||||
Phase 1 | 20 | vuhqrsocmc(oikqrzepbs) = zmmjokweal dfhaotnanl (caybelmyek ) View more | Positive | 18 Jan 2024 | |||
Phase 1 | - | pzbfwpofrs(rzalntsjjm) = qaxwyhqohn wwhwnitmrq (fxljuyhmgu, 12.5 - notestimable) | Positive | 01 Jan 2024 | |||
Phase 1/2 | KRAS G12C mutant Non-small Cell Lung Cancer KRAS G12C mutation | PD-L1 | 174 | hbpqrqvciu(cfbgyvpsja) = The most common side effects included diarrhea xpaffrylvf (blxbpsgldp ) View more | - | 01 Jan 2024 | ||
Phase 1 | - | 146 | (Treatment A) | vnfsffurqx(ivezackimk) = bfkeozyipf kxmofxtold (awitevydzn, qhnugttunh - bjaqusyghj) View more | - | 14 Dec 2023 | |
(Treatment B) | vnfsffurqx(ivezackimk) = qnezbedlec kxmofxtold (awitevydzn, rzerbmabhz - kmwfgxnusk) View more |